Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
enGene Therapeutics Inc. - Common Stock
(NQ:
ENGN
)
1.790
+0.020 (+1.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about enGene Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
Next >
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
August 04, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
July 16, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
June 15, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
June 02, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
↗
May 30, 2026
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Via
The Motley Fool
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
↗
May 30, 2026
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.
Via
The Motley Fool
ENGN Investors Have Opportunity to Join enGene Therapeutics Inc. Fraud Investigation with the Schall Law Firm
May 29, 2026
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
May 26, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of enGene Therapeutics Inc. - ENGN
May 19, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Kestra Medical Grew Revenue 63%. One Fund Still Trimmed 351,000 Shares
↗
May 15, 2026
Kestra Medical Technologies develops advanced wearable cardiac devices and digital health solutions for cardiovascular care providers.
Via
The Motley Fool
Topics
Regulatory Compliance
Unusual volume stocks are being observed in Monday's session.
↗
May 11, 2026
Via
Chartmill
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain
↗
May 08, 2026
enGene (NASDAQ:ENGN) reported preliminary data from the pivotal Cohort 1 of its ongoing Phase 2 LEGEND trial evaluating detalimogene voroplasmide, or detalimogene, in patients with high-risk...
Via
MarketBeat
Which stocks are experiencing notable movement on Thursday?
↗
May 07, 2026
Via
Chartmill
Top stock movements in today's session.
↗
May 07, 2026
Via
Chartmill
There are notable gap-ups and gap-downs in today's session.
↗
May 07, 2026
Via
Chartmill
Which stocks are moving before the opening bell on Thursday?
↗
May 07, 2026
Via
Chartmill
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
May 07, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
enGene Announces Name Change to enGene Therapeutics Inc.
April 07, 2026
From
enGene Therapeutics Inc.
Via
Business Wire
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
↗
March 21, 2026
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
Via
The Motley Fool
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
March 09, 2026
From
enGene Holdings Inc.
Via
Business Wire
enGene to Participate in Upcoming Investor Conferences
February 20, 2026
From
enGene Holdings Inc.
Via
Business Wire
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
February 04, 2026
From
enGene Holdings Inc.
Via
Business Wire
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
January 20, 2026
From
enGene Holdings Inc.
Via
Business Wire
enGene Reports Full Year 2025 Financial Results and Provides Business Update
December 22, 2025
From
enGene Holdings Inc.
Via
Business Wire
enGene’s Detalimogene Selected for FDA Manufacturing Pilot Program to Support Manufacturing Readiness
December 02, 2025
From
enGene Holdings Inc.
Via
Business Wire
enGene to Present at the Piper Sandler 37th Annual Healthcare Conference
November 25, 2025
From
enGene Holdings Inc.
Via
Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
November 18, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
November 13, 2025
Via
Benzinga
enGene Announces Pricing of $130 Million Public Offering of Common Shares and Pre-Funded Warrants
November 13, 2025
From
enGene Holdings Inc.
Via
Business Wire
enGene Announces Proposed Public Offering of Common Shares
November 12, 2025
From
enGene Holdings Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
